Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02754752 | Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment | active not recruiting | Phase 2 | 111 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02876107 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | active not recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06840483 | Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | active not recruiting | Phase 2 | 66 | BicycleTx LimitedINDUSTRY | 7 | Apr 15, 2026 | clinicaltrials |
| NCT07045311 | JS207 Combination Therapy in Triple-negative Breast Cancer | recruiting | Phase 2 | 80 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04920708 | Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression(FAIM) | active not recruiting | Phase 2 | 57 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07528898 | Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. | not yet recruiting | Phase 2 | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02802423 | Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. | not yet recruiting | Phase 1 / Phase 2 | 44 | BioLite, Inc.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT03650894 | Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | active not recruiting | Phase 2 | 30 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05095207 | Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 42 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05837455 | NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer | recruiting | Phase 2 | 81 | Washington University School of MedicineOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810804 | A Phase IIa Study to Evaluate NBQ72S | recruiting | Phase 2 | 10 | Nantong Bencao Quadriga Medical Technology Co. Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07164976 | Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 86 | Nagoya City UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04841148 | Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer(PALAVY) | recruiting | Phase 2 | 96 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06702618 | Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer | active not recruiting | Phase 2 | 33 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07227233 | Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.(AIM-BRIGHT) | recruiting | Phase 2 | 105 | University of California, San DiegoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07112053 | A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer | recruiting | Phase 2 | 40 | University of WashingtonOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07510802 | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03428802 | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | active not recruiting | Phase 2 | 21 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07509515 | QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. | not yet recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT04569747 | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer(ADEPT) | active not recruiting | Phase 2 | 393 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07492394 | Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer | recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05735080 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer(INX-315-01) | recruiting | Phase 1 / Phase 2 | 150 | Incyclix BioINDUSTRY | 2 | Apr 1, 2026 | clinicaltrials |
| NCT05769010 | Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases | recruiting | Phase 2 | 150 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06365788 | Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer(ABBICAR) | recruiting | Phase 2 | 53 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06768931 | Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer | recruiting | Phase 2 | 192 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07074106 | TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC(DespaTIL) | recruiting | Phase 2 | 40 | D'Or Institute for Research and EducationOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07455955 | Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile | recruiting | Phase 2 | 200 | Chinese University of Hong KongOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02890082 | Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer(PRESAGE) | active not recruiting | Phase 2 | 102 | Institut Cancerologie de l'OuestOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06450873 | Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT01525966 | Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer | active not recruiting | Phase 2 | 67 | City of Hope Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03449238 | Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 41 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07499999 | Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer(BabyTEARS) | not yet recruiting | Phase 2 | 140 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03568422 | CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 37 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07371585 | Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management(TOP-REAL) | recruiting | Phase 2 | 300 | SOLTI Breast Cancer Research GroupOTHER | 3 | Mar 27, 2026 | clinicaltrials |
| NCT07498478 | Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment | recruiting | Phase 2 | 94 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07492589 | Photo-Acoustic and Ultrasonographic Mammoscope(PAUS) | recruiting | Phase 2 | 180 | Franciscus Gasthuis & Vlietland (Hospital)OTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07335081 | ctDNA in HER2+ EBC Neoadjuvant Treatment | recruiting | Phase 2 | 60 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05748834 | Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | recruiting | Phase 2 | 36 | SCRI Development Innovations, LLCOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06568705 | Hypofractionated Online Adaptive Radiotherapy of Breast Cancer | recruiting | Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07486089 | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)(DUAL-NK-BC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05020574 | Microbiome and Association With Implant Infections | recruiting | Phase 2 | 200 | University of California, San FranciscoOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02482376 | Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer | active not recruiting | Phase 2 | 110 | Duke UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06650748 | Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer(NeoMARS) | enrolling by invitation | Phase 2 | 100 | Peking UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05227664 | A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer | active not recruiting | Phase 2 | 120 | AkesoINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07471776 | Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07466303 | Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer | not yet recruiting | Phase 2 | 84 | Xijing HospitalOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT02712723 | Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer(FELINE) | active not recruiting | Phase 2 | 121 | Qamar KhanOTHER | 1 | Mar 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 15, 2026source: clinicaltrials